Navigation Links
HPV testing: IQWiG still sees indications of a benefit in primary screening
Date:6/11/2014

The Institute for Quality and Efficiency in Health Care (IQWiG) assessed current study results on the benefit of a test for human papillomavirus (HPV) and examined whether its first assessment from January 2012 is still valid. The rapid report published by the Institute on 11 June 2014 answers this question with "yes". IQWiG still sees indications that precursors of cervical cancer can be detected and treated earlier and consequently tumours occur less often in women who underwent this testing.

HPV testing is not reimbursed by SHI funds

In screening for cervical cancer, the German statutory health insurance (SHI) funds currently offer an annual cytologic examination of mucosal cells from a smear taken from the neck of the womb (cervix). This test is called a Pap smear. Since it became known that infection with HPV is the main risk factor for developing cervical cancer, experts have been discussing whether HPV testing is also a suitable screening method or is even superior to a cytologic test. The SHI funds currently only reimburse HPV testing in exceptional cases, for example, in cases where the result of a Pap smear is unclear.

New analysis of large study

IQWiG conducted a new search for studies comparing primary screening strategies for cervical cancer based on different screening tests: a strategy including HPV testing alone or in combination with cytology-based testing and a strategy including cytology-based testing alone.

In this update search, they identified no studies that had not already been included in the first assessment. However, they were now able to include the final analysis of one of the largest studies (POBASCAM), for which only an interim analysis had been available in 2011.

Fewer cancer diagnoses in the second screening round

Also under inclusion of the new data, the number of diagnoses for invasive cervical cancer in the second screening round was lower in the HPV group than in the group of women who had only been examined with a cytology-based screening strategy (e.g. Pap smear) in the first screening round. This also applies to the so-called "composite outcome", which not only comprised tumours, but also advanced precursors of cancer. IQWiG therefore determined an indication of a benefit in each case.

There are still no data or no evaluable data available on mortality, quality of life and potential harm.

As the screening strategies applied in the studies varied greatly and could therefore not be compared with each other, the results still do not allow a recommendation for a specific screening strategy in the German health care system.

Process of report production

The Federal Joint Committee (G-BA) commissioned IQWiG to prepare the report in an accelerated process, known as a "rapid report". Unlike the normal procedure, no preliminary reports are published in this case. Although a draft version of the report is reviewed by external experts, no hearing at which all interested parties can comment takes place.

IQWiG sent the first benefit assessment to the commissioning agency in November 2011 and published it in January 2012. In October, the G-BA commissioned IQWiG to update its report using the same methodological approach. The present report was sent to the G-BA in mid-May 2014.


'/>"/>
Contact: Dr. Anna-Sabine Ernst
presse@iqwig.de
49-022-135-6850
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Related medicine news :

1. HIV self-testing: The key to controlling the global epidemic
2. IQWiG: First health economic evaluation completed
3. IQWiG publishes new version of its General Methods
4. Men Can Still Ask for PSA Test, and Some Should, Doctors Say
5. Fewer Stillbirths Among Pregnant Women Vaccinated Against Flu
6. Many Still Tanning, Despite Dangers, Survey Finds
7. Once-Obese Women Still Face Stigma, Study Finds
8. Smallest, Largest Fetuses at Higher Risk of Stillbirth
9. People With Darker Skin Still at Risk for Melanoma
10. In-Person Bullying Still Bigger Problem Than Cyberbullying: Expert
11. More Americans Walking, But Still Not Enough, CDC Says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... A new partnership between ... they no longer use or need, from clothes to couches to dressers and bicycles. ... and take them to the nearest Goodwill donation center through February 28th. , ...
(Date:1/20/2017)... Miami, Florida (PRWEB) , ... January 20, 2017 , ... ... in head lice cases in families with school-aged children since the holiday season. ... spend the holidays with their families, sharing hugs and taking photos, which is the ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... its sugar-free alternative VW+ 002. The drinks have been produced in collaboration with ... to perform during your workout. , After a successful launch in Sweden last ...
(Date:1/20/2017)... ... 2017 , ... D R Burton Healthcare Products LLC, makers ... in a study indicating superior performance against competitive products in secretion clearance. ... Positive Expiratory Pressure Devices During Simulated Breathing“ was published in the winter issue ...
(Date:1/20/2017)... ... January 20, 2017 , ... “God's Miracle Man: Against All Odds”: an ... of published author, Keith C. A. Tucker, son of Minister Delores Pinnock and a ... by Reverend Mark Hardy , “While sitting up in bed, I felt a pounding ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 19, 2017 Shire plc (LSE: ... U.S. Food and Drug Administration (FDA) has acknowledged receipt ... Application (NDA) for SHP465, a long-acting, triple-bead, mixed amphetamine ... once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is ... 20, 2017, the designated Prescription Drug User Fee Act ...
(Date:1/19/2017)... 19, 2017 Pfizer joins ... Milner Therapeutics Consortium   Major research ... Cambridge   The Milner Therapeutics ... ) as a partner to the Milner Therapeutics Consortium. ... the efficient transfer of materials between industry and academia ...
(Date:1/19/2017)... Florida , January 19, 2017 ... Trump administration appears serious about reducing the FDA,s ... and innovation in the medical drug industry, many ... ahead with new clinical trials and development of ... companies forging ahead with recent developments include:  Moleculin ...
Breaking Medicine Technology: